The estimated Net Worth of Matthew R Patterson is at least $1.93 Million dollars as of 26 December 2019. Mr. Patterson owns over 162,538 units of Homology Medicines Inc stock worth over $243,156 and over the last 17 years he sold FIXX stock worth over $1,459,819. In addition, he makes $223,638 as Independent Director at Homology Medicines Inc.
Sign up
Mr. Patterson FIXX stock SEC Form 4 insiders trading
Matthew has made over 27 trades of the Homology Medicines Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 162,538 units of FIXX stock worth $503,868 on 26 December 2019.
The largest trade he's ever made was exercising 162,538 units of Homology Medicines Inc stock on 26 December 2019 worth over $503,868. On average, Matthew trades about 12,033 units every 98 days since 2007. As of 26 December 2019 he still owns at least 261,458 units of Homology Medicines Inc stock.
You can see the complete history of Mr. Patterson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Patterson biography
Matthew R. Patterson serves as Independent Director of the Company. Mr. Patterson is the co-founder of Audentes Therapeutics, Inc., a biotechnology company, and has served in the role of Strategic Advisor since January 2020. Previously, he served as its Chief Executive Officer from November 2012 until Audentes’ acquisition by Astellas Pharma Inc. in January 2020. Mr. Patterson also served as Audentes’ Chairman of the board of directors and formerly served as President until May 2018. Prior to that, Mr. Patterson was the Entrepreneur-In-Residence at OrbiMed Advisors LLC. Prior to OrbiMed, Mr. Patterson served in roles at Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Genzyme Corporation. Mr. Patterson holds a B.A. from Bowdoin College.
What is the salary of Matthew Patterson?
As the Independent Director of Homology Medicines Inc, the total compensation of Matthew Patterson at Homology Medicines Inc is $223,638. There are 11 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of $5,062,880.
How old is Matthew Patterson?
Matthew Patterson is 48, he's been the Independent Director of Homology Medicines Inc since 2018. There are 17 older and 1 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
What's Matthew Patterson's mailing address?
Matthew's mailing address filed with the SEC is C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD, MA, 01730.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management..., and Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Mr. Patterson stock trades at Amicus Therapeutics Inc and Homology Medicines Inc
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer